{"organizations": [], "uuid": "97116475499ac7f8850f08fc33e08ee56e433925", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180129.html", "section_title": "Archive News &amp; Video for Monday, 29 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-mylan-and-biocon-receive-positive/brief-mylan-and-biocon-receive-positive-chmp-opinion-for-semglee-biosimilar-insulin-glargine-idUSFWN1PO0DE", "country": "US", "domain_rank": 408, "title": "BRIEF-Mylan And Biocon Receive Positive CHMP Opinion For Semglee, Biosimilar Insulin Glargine", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.381, "site_type": "news", "published": "2018-01-29T19:16:00.000+02:00", "replies_count": 0, "uuid": "97116475499ac7f8850f08fc33e08ee56e433925"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-mylan-and-biocon-receive-positive/brief-mylan-and-biocon-receive-positive-chmp-opinion-for-semglee-biosimilar-insulin-glargine-idUSFWN1PO0DE", "ord_in_thread": 0, "title": "BRIEF-Mylan And Biocon Receive Positive CHMP Opinion For Semglee, Biosimilar Insulin Glargine", "locations": [], "entities": {"persons": [{"name": "biosim", "sentiment": "negative"}], "locations": [{"name": "australia", "sentiment": "none"}, {"name": "canada", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "biocon receive positive chmp opinion for semglee", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "biocon ltd", "sentiment": "negative"}, {"name": "mylan", "sentiment": "negative"}, {"name": "biocon", "sentiment": "negative"}, {"name": "mylan nv", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 29 (Reuters) - Biocon Ltd:\n* MYLAN AND BIOCON RECEIVE POSITIVE CHMP OPINION FOR SEMGLEEâ„¢, BIOSIMILAR INSULIN GLARGINE\n* MYLAN NV - CHMP POSITIVE OPINION WILL BE CONSIDERED BY EUROPEAN COMMISSION\n* MYLAN NV - EUROPEAN COMMISSION DECISION ON APPROVAL IS EXPECTED IN APRIL\n* MYLAN NV - EUROPEAN COMMISSION DECISION ON APPROVAL IS EXPECTED IN APRIL\n* MYLAN - IN ADDITION TO EUROPEAN SUBMISSION, MARKETING APPLICATIONS FOR SEMGLEE BEEN SUBMITTED IN AUSTRALIA, CANADA, U.S. & PLANNED FOR KEY EMERGING MARKETS Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-29T19:16:00.000+02:00", "crawled": "2018-01-30T18:44:04.004+02:00", "highlightTitle": ""}